13F filer · CIK 1224962
PERCEPTIVE ADVISORS LLC
NEW YORK, NY · filing since Q2 2013 · last filing Aug 14, 2026
Reported value
$6.7B
+$1.5B vs prior
Positions
109
New / sold out
29 / 14
Added / reduced
30 / 26
Turnover
18.1%
buys $1.6B · sells $1.1B
Top-10 weight
47.3%
Biggest buys vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| New | ASCENDIS PHARMA A/S | +1,163,721 | – | +$310.4M |
| New | KARDIGAN INC | +8,200,662 | – | +$195.6M |
| New | AVALYN PHARMACEUTICALS INC | +2,675,296 | – | +$88.1M |
| Added | RELAY THERAPEUTICS INC | +4,355,046 | +44.7% | +$81.5M |
| Added | TANGO THERAPEUTICS INC | +2,568,847 | +317.9% | +$80.3M |
| New | BIOGEN INC | +276,173 | – | +$59.7M |
| Added | REVOLUTION MEDICINES INC | +269,000 | +104.0% | +$50.4M |
| New | UNITEDHEALTH GROUP INC | +116,806 | – | +$48.5M |
| Added | SPYRE THERAPEUTICS INC | +536,271 | +14.2% | +$47.6M |
| New | SPDR SERIES TRUSTPUT | +300,000 | – | +$47.5M |
49 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Biggest sells vs Q1 2026
| Change | Security | Shares change | Change % | Est. trade value |
|---|---|---|---|---|
| Sold out | ASCENDIS PHARMA A/S | -1,531,421 | -100.0% | $-350.3M |
| Sold out | CENTESSA PHARMACEUTICALS PLC | -5,258,903 | -100.0% | $-208.9M |
| Reduced | DYNE THERAPEUTICS INC | -1,979,604 | -42.4% | $-44.0M |
| Sold out | ENGENE HOLDINGS INC | -5,827,506 | -100.0% | $-39.7M |
| Reduced | GUARDANT HEALTH INC | -258,673 | -86.2% | $-38.8M |
| Sold out | DAY ONE BIOPHARMACEUTICALS I | -1,755,799 | -100.0% | $-37.6M |
| Reduced | ABIVAX SA | -254,884 | -77.5% | $-34.0M |
| Reduced | APOGEE THERAPEUTICS INC | -232,271 | -15.1% | $-30.8M |
| Reduced | PROTAGONIST THERAPEUTICS INC | -249,000 | -20.2% | $-30.5M |
| Sold out | BRIGHT MINDS BIOSCIENCES INC | -377,544 | -100.0% | $-27.5M |
30 more rows. Subscribe for $29/month to see every row, download the data and use the API.
Estimated trade value = change in shares × this quarter's implied price. 13F filings show quarter-end positions, not individual trades.
Reported value by quarter
Holdings · Q2 2026
| # | Security | Shares | Value | Weight |
|---|---|---|---|---|
| 1 | PRAXIS PRECISION MEDICINES ICOM NEW | 2,035,986 | $681.6M | 10.23% |
| 2 | SPYRE THERAPEUTICS INCCOM NEW | 4,319,496 | $383.5M | 5.76% |
| 3 | CELCUITY INCCOM | 3,197,200 | $334.5M | 5.02% |
| 4 | ASCENDIS PHARMA A/SORD SHS | 1,163,721 | $310.4M | 4.66% |
| 5 | RHYTHM PHARMACEUTICALS INCCOM | 2,586,295 | $287.2M | 4.31% |
| 6 | ROIVANT SCIENCES LTDSHS | 8,085,461 | $286.1M | 4.30% |
| 7 | RELAY THERAPEUTICS INCCOM | 14,106,187 | $263.9M | 3.96% |
| 8 | TRAVERE THERAPEUTICS INCCOM | 3,752,574 | $213.2M | 3.20% |
| 9 | KARDIGAN INCCOM | 8,200,662 | $195.6M | 2.94% |
| 10 | NUVALENT INCCOM | 1,580,505 | $195.2M | 2.93% |
99 more rows. Subscribe for $29/month to see every row, download the data and use the API.